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ABSTRACT
Study queStion
How safe is live attenuated influenza vaccine (LAIV), 
which contains egg protein, in young people with egg 
allergy?
MethodS
In this open label, phase IV intervention study, 779 
young people (2-18 years) with egg allergy were 
recruited from 30 UK allergy centres and immunised 
with LAIV. The cohort included 270 (34.7%) young 
people with previous anaphylaxis to egg, of whom 157 
(20.1%) had experienced respiratory and/or 
cardiovascular symptoms. 445 (57.1%) had doctor 
diagnosed asthma or recurrent wheeze. Participants 
were observed for at least 30 minutes after vaccination 
and followed-up by telephone 72 hours later. 
Participants with a history of recurrent wheeze or 
asthma underwent further follow-up four weeks later. 
The main outcome measure was incidence of an 
adverse event within two hours of vaccination in young 
people with egg allergy.
Study anSwer and liMitationS
No systemic allergic reactions occurred (upper 95% 
confidence interval for population 0.47% and in 
participants with anaphylaxis to egg 1.36%). Nine 
participants (1.2%, 95% CI 0.5% to 2.2%) 
experienced mild symptoms, potentially consistent 
with a local, IgE mediated allergic reaction. Delayed 
events potentially related to the vaccine were 
reported in 221 participants. 62 participants (8.1%, 
95% CI for population 6.3% to 10.3%) experienced 
lower respiratory tract symptoms within 72 hours, 
including 29 with parent reported wheeze. No 
participants were admitted to hospital. No increase 
in lower respiratory tract symptoms occurred in the 
four weeks after vaccination (assessed with asthma 
control test). The study cohort may represent young 
people with more severe allergy requiring specialist 
input, since they were recruited from secondary and 
tertiary allergy centres.
what thiS Study addS
LAIV is associated with a low risk of systemic allergic 
reactions in young people with egg allergy. The vaccine 
seems to be well tolerated in those with well controlled 
asthma or recurrent wheeze.
Funding, CoMpeting intereStS, data Sharing
This report is independent research commissioned 
and funded by a Department of Health policy research 
programme grant to the National Vaccine Evaluation 
Consortium. Additional funding was provided by the 
NIHR Clinical Research Networks, Health Protection 
Scotland (Edinburgh site), and Health & Social Care 
Services in Northern Ireland (Belfast site). PJT and MEL 
had support from the Department of Health for the 
submitted work; PJT has received research grants from 
the Medical Research Council and NIHR. No additional 
data available.
Study regiStration
ClinicalTrials.gov (NCT02111512) and the EU Clinical 
Trials Register EudraCT (2014-001537-92).
Introduction
Epidemiological data and mathematical modelling 
indicate children are the main spreaders of influenza 
infection.1  Vaccinating children therefore provides the 
most effective method for interrupting transmission 
and achieving disease control. This was recognised by 
the Joint Committee for Vaccination and Immunisation, 
an independent expert advisory committee to the UK 
Departments of Health, which in 2012 recommended 
annual vaccination of all children aged 2-16 years with 
the live attenuated influenza vaccine (LAIV).2  This vac-
cine is given through the intranasal route and has high 
efficacy against influenza in young people aged 2-17 
years,3 4  with a good safety profile, similar to that of 
inactivated influenza vaccines.5-9  The Joint Committee 
for Vaccination and Immunisation considered that 
extending the influenza vaccine programme to include 
both high risk and low risk children was likely to be safe 
and cost effective, providing direct protection to the 
vaccinated child as well as indirect protection by lower-
ing influenza transmission from vaccinated children 
and adolescents to others, including those in clinical 
risk groups.2
In common with other influenza vaccines licensed 
for use in young people, LAIV is grown in hens’ eggs 
and contains egg proteins, such as ovalbumin.10  There 
is now a consensus that inactivated influenza vaccines 
with a low ovalbumin content (<0.12 μg/mL, equivalent 
WhAT IS AlReAdy knoWn on ThIS TopIC
Egg allergy is common, affecting 2-6% of preschool children
An intranasal vaccine (live attenuated influenza vaccine, LAIV) has been introduced 
into the UK paediatric vaccination schedule, but there are limited safety data for its 
use in young people with egg allergy and/or asthma
Some guidelines recommend against using LAIV in children under 5 years with a 
history of recurrent wheeze or asthma
WhAT ThIS STudy AddS
LAIV did not cause any systemic allergic reactions in this cohort of young people 
with egg allergy
LAIV seems to be well tolerated in young people with a diagnosis of asthma or 
recurrent wheeze, provided that lower respiratory symptoms are well controlled
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to 0.06 μg for a 0.5 mL dose) are safe for use in people 
with egg allergy,11 12  with the proviso that “in all settings 
providing vaccination, facilities should be available 
and staff trained to recognise and treat anaphylaxis.”11 
Until recently, there was no safety data on the use of 
LAIV in young people with egg allergy, and egg allergy 
remains listed as a contraindication for LAIV in the 
summary of product characteristics.10  For the 2015/16 
influenza season, seasonal influenza vaccination will 
be offered to all 2 to 4 year olds, and those in school 
years 1 and 2, using quadrivalent LAIV unless otherwise 
contraindicated.13  The prevalence of egg allergy is esti-
mated to be 2.5% in this age group,14 so on the basis of 
UK 2013 population data, there are 100 000 young peo-
ple with egg allergy in whom vaccination with LAIV 
would therefore be contraindicated.
Young people with egg allergy often have concomi-
tant diseases, including eczema and recurrent wheeze. 
Some guidelines recommend against the use of LAIV in 
young people with recurrent wheeze, owing to limited 
evidence from a clinical trial15  that the vaccine may 
induce wheezing in younger children.16 These are 
important barriers to achieving successful implementa-
tion of the immunisation programme in the community 
and primary care settings. To address this and provide 
data to underpin an evidence based change in guid-
ance, we assessed the safety of using LAIV in young 
people with egg allergy in a large, multicentre, interven-
tional study.
Methods
We undertook a phase IV open label study of LAIV in 
young people with egg allergy, during the influenza sea-
son (September 2014 to February 2015) across 30 hospi-
tals (specialist and non-specialist clinics) in the United 
Kingdom. Eligible participants were aged 2-18 years, 
with a current doctor diagnosis of egg allergy. We also 
included young people with a history of anaphylaxis to 
egg or a history of severe but stable asthma. Anaphy-
laxis was defined using World Allergy Organization cri-
teria.17  We classified asthma according to current 
treatment at time of immunisation, using the British 
Thoracic Society (BTS) and Scottish Intercollegiate 
Guidelines Network (SIGN) guidelines.18
Participants were excluded if they had previously 
required invasive ventilation for an anaphylactic reac-
tion to egg, had severe asthma (defined as BTS/SIGN 
step 5 treatment with poor control, assessed by the 
attending specialist or with an asthma control test score 
of <20),19 or contraindication to LAIV (other than egg 
allergy). Vaccination was deferred for acute febrile ill-
ness; wheeze in the preceding 72 hours, or acute asthma 
symptoms requiring corticosteroids in the previous two 
weeks; and receipt of antihistamine within the previous 
four days (owing to the possibility that any allergic 
symptoms might be masked).
The parent or guardian of each participant gave writ-
ten informed consent. Young people over 8 years were 
encouraged to provide assent. The study was registered 
with ClinicalTrials.gov (NCT02111512) and the EU Clini-
cal Trials Register EudraCT (2014-001537-92).
procedures
We recorded baseline measurements (blood pressure, 
heart rate, respiratory rate, oxygen saturations), with 
simultaneous clinical respiratory and dermatological 
assessment. Quadrivalent LAIV (Fluenz Tetra, MedIm-
mune LLC, Nijmegen, Netherlands; distributed by Astra 
Zeneca, London UK; produced for the 2014/15 influenza 
season) was administered according to the approved 
summary of product characteristics.10  We observed par-
ticipants for at least 30 minutes for symptoms of local or 
systemic allergic reaction, and documented clinical 
observations and symptom scoring (total nasal symp-
tom score)20  on a dedicated study case report form. 
After at least 72 hours we telephoned the parents to doc-
ument any delayed symptoms. In participants with a 
history of asthma or recurrent wheeze, we administered 
the asthma control test before vaccination and four 
weeks later. This test is a validated tool providing an 
assessment of asthma symptoms over the preceding 
four weeks.19  We offered a second dose of LAIV to par-
ticipants in a high risk clinical group who had not 
received a previous seasonal influenza vaccine at least 
four weeks later, in line with national guidelines.12
outcomes
The primary outcome was the incidence of allergic reac-
tion as an adverse event following immunisation (AEFI) 
occurring within two hours of vaccination, according to 
symptoms listed in the Brighton Collaboration case 
definition for systemic allergic reaction (anaphylaxis) 
as an AEFI.21  We defined any reaction not meeting the 
case definition for anaphylaxis as a possible non-ana-
phylactic reaction. A change in total nasal symptom 
score of 3 or more was taken as indicative of a possible 
local (nasal) allergic response.20
Secondary outcomes were incidence of delayed symp-
toms occurring up to 72 hours after vaccination with 
LAIV (including those related to non-allergic factors); 
change in asthma control test score before and one 
month after vaccination in participants with a history of 
asthma or recurrent wheeze, or both. In children under 
12 years, we compared only the subscore relating to 
parental assessment of symptoms. An independent data 
monitoring committee reviewed all adverse events, and 
assigned causality in conjunction with local study teams.
Statistical analyses
Analyses were planned prospectively and detailed in a 
statistical analysis plan. We estimated the incidence of 
reactions to LAIV (both immediate and delayed) with 
two sided exact 95% confidence intervals. For subgroup 
analyses, we used a two sided Fisher’s exact test to com-
pare the incidence of reactions between different 
cohorts. Subgroup analyses included age group (2 5, 6 11, 
12 17 years), certainty of true clinical allergy (on the 
basis of reaction to egg within the previous 12 months 
and/or evidence of >95% likelihood of egg allergy 
according to published criteria),22 23 history of anaphy-
laxis to egg, history of previous reaction to airborne 
traces of egg, tolerance to extensively heated egg, 
 previous receipt of any influenza vaccine (inactivated or 
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LAIV) or LAIV alone, presence of doctor diagnosed 
asthma or recurrent wheeze, and ovalbumin content of 
LAIV batch used. We used McNemar’s exact test to 
assess change in asthma control test score.
Sample size was considered for historical compari-
sons and was based on the precision around an esti-
mate of zero. If there were no allergic reactions in a 
sample size of 730, then this would provide confidence 
(based on the upper end of the two sided 95% confi-
dence interval) that the true rate of allergic reaction to 
LAIV in young people with egg allergy within the popu-
lation was no more than 0.5%. The analysis dataset was 
as treated and with the relevant safety data measured.
patient involvement
Parents of young people with egg allergy were involved 
in the design of the study and the development of study 
information leaflets, and in setting the research ques-
tion. Results of the study will be disseminated through 
patient support organisations (Allergy UK and the Ana-
phylaxis Campaign) through electronic newsletters and 
social media.
Results
Overall, 779 children with egg allergy were enrolled and 
received at least one dose of LAIV between September 
2014 and February 2015. The median age of the cohort 
was 5.3 years (range 2-18 years) and 508 (65.2%) were 
male. Three hundred and sixty nine (47.4%) had received 
influenza vaccination in previous years, of whom 188 
had been given LAIV. Most LAIV in  circulation in the UK 
does not contain detectable  ovalbumin (personal 
 communication, Department of Health). For this study, 
we sourced vaccine with detectable ovalbumin. In 667 
(85.6%) children the batch of LAIV used contained >0.3 
ng/mL ovalbumin, and 511 (65.6%) received a dose con-
taining 1-1.93 ng/mL ovalbumin.
All the participants were excluding egg from their 
diet at the time of immunisation. Three hundred and 
fifteen (40.4%) had experienced an allergic reaction to 
egg in the past 12 months, including 40 (5.1%) at formal, 
in-hospital food challenge. A total of 138 (17.7%) had not 
reacted to egg in the past 12 months but had evidence of 
sensitisation above the published criteria for more than 
95% positive predictive values for clinical egg allergy.22 23 
Thus, 453 (58.2%) young people met the criteria consis-
tent with more than a 95% likelihood of clinical egg 
allergy within the 12 months before vaccination. An 
allergy specialist verified the egg allergy diagnosis in 
673 (86.4%) participants. Of the remainder, 90 had 
received a diagnosis by a general paediatrician and 16 
by their general practitioner; within this subgroup, only 
42 (5.3% of total cohort) did not meet the 95% positive 
predictive value criteria.
The cohort included 270 (34.7%) young people with a 
history of anaphylaxis to egg, of whom 157 (20.1%) had 
experienced respiratory and/or cardiovascular symp-
toms with egg ingestion. Fifty three (6.8%) participants 
had experienced World Allergy Organization grade 3+ 
reactions (stridor with respiratory compromise, wheeze 
not responsive to initial bronchodilator treatment, or 
collapse/hypotension). Only 56 (7.2%) had never eaten 
egg and had a diagnosis based on predictive allergy 
testing alone. Four hundred and forty five participants 
(57.1%) had a doctor diagnosis of asthma or recurrent 
wheeze, of whom 361 (46.3% of total cohort) were using 
daily preventer treatment (BTS/SIGN step 2+) and 143 
(18.4%) BTS/SIGN step 3+ treatment. Three hundred 
and seventy seven (48.4%) had allergic rhinitis, 463 
(59.4%) had atopic eczema, and 435 (55.8%) were aller-
gic to three or more food groups.
A second LAIV dose was administered to 30 young 
people: 28 vaccine naïve participants who required a 
further dose according to clinical risk, and two partici-
pants who underwent subsequent allergy skin testing, 
including nasal challenge with vaccine, owing to possi-
ble systemic allergic reaction to LAIV (fig 1). A further 15 
children were eligible for a second dose, but did not 
receive it owing to expiry of the vaccine (nine partici-
pants) or the family declining a second visit for a further 
dose (six participants).
primary outcome: immediate adverse events 
following immunisation
Seventeen adverse events were recorded in 17 individ-
ual participants within two hours of vaccination (see 
supplementary table E1). Six were not consistent with a 
potential, IgE mediated allergic response as defined by 
international consensus criteria.21 Two participants 
reported skin symptoms (urticaria/angioedema) 
between 30 and 120 minutes after LAIV; both under-
went subsequent specialist allergy testing four weeks 
later (to LAIV and excipients, all of which produced 
Analysed (n=43)
Required 1 dose of vaccine only (n=736):
  Received allocated intervention (n=734)
  Received second dose for evaluation of possible
    systemic reaction to initial dose (n=2)
Required 2 doses of vaccine (n=43):
  Received allocated intervention (n=28)
  Received one dose only (n=15):
    Vaccine expired before dose (n=9)
    Declined second dose (n=6)
Screened for eligibility (n=1830)
Follow-up at 72 hours aer dose (n=720)
  Lost to follow-up (unable to contact) (n=16)
Follow-up at 72 hours aer dose 2 (n=2)
  Lost to follow-up aer dose 2 (n=0)
Follow-up at 72 hours aer dose 1 (n=42)
  Lost to follow-up aer dose 1 (n=1)
Follow-up at 72 hours aer dose 2 (n=27)
  Lost to follow-up aer dose 2 (n=1)
Analysed (n=736)
No response to invitation (n=1038)
Assessed for eligibility (n=792)
Received vaccine (n=779)
Children receiving dose 1 (n=779, with follow-up at 72 hours (n=762; 98%))
Children receiving dose 2 (n=28, with follow-up at 72 hours (n=27; 96%))
Excluded as not eligible (n=13)
Fig 1 | Flow of participants through study. 13 children were consented but not eligible for 
study: six had recently used antihistamines (family declined further study appointment), 
five refused after parental consent had been obtained; two had unstable asthma (and were 
given inactivated influenza vaccine instead)
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negative results) and were given a second dose of LAIV 
which was tolerated without any observed adverse 
symptoms in the two hours after vaccination. In one 
case, the initial reaction could be attributed to uninten-
tional consumption of cow’s milk, to which the partici-
pant was allergic. Therefore, no participant experienced 
a systemic reaction attributed to LAIV; the 95% upper 
confidence interval for the incidence of a systemic aller-
gic reaction (including anaphylaxis) to LAIV in partici-
pants with egg allergy was therefore 0.47%. In 
participants with a history of anaphylaxis, the equiva-
lent 95% upper confidence interval was 1.36%.
Nine participants (1.2%, 95% confidence interval 
0.5% to 2.2%) experienced an immediate AEFI of possi-
ble allergic cause. These reactions (four rhinitis, four 
localised/contact urticaria, one oropharyngeal itch) 
were mild, self limiting, and occurred within 30 min-
utes of immunisation with LAIV. Participants with a 
history of reaction to aerosolised egg had a higher inci-
dence of possible reaction (3/70 v 6/709, P=0.04), but 
otherwise no risk factors were identified for occurrence 
of an acute adverse event, allergic or otherwise, when 
participants were assessed for age, previous anaphy-
laxis to egg, previous influenza vaccination (any, or pre-
vious LAIV), presence of doctor diagnosed asthma or 
recurrent wheeze or allergic rhinitis, or level of ovalbu-
min in the administered dose of LAIV (P>0.05 for all 
comparisons, see supplementary table E2).
delayed adverse events (2-72 hours after 
vaccination)
No serious adverse events attributable to LAIV occurred 
during the study. Delayed events potentially related to 
the vaccine were reported in 221 participants (table 1). 
Sixty two children (8.1%, 95% confidence interval for 
population 6.3% to 10.3%) experienced lower respira-
tory tract symptoms within 72 hours after vaccination, 
including 29 with parent reported wheeze (3.8%, 2.6% 
to 5.4%). No risk factors were identified for occurrence 
of delayed events, although there was a trend towards 
an increased rate of lower respiratory tract symptoms in 
younger children (P=0.07, see supplementary table E3). 
Some guidelines have suggested that children under 5 
years with a history of wheezing are at risk of develop-
ing wheeze after vaccination with LAIV. To assess this, 
in an additional exploratory analysis we compared the 
rate of lower respiratory tract symptoms in children 
with asthma or recurrent wheeze: children under 5 
years were slightly more likely to develop lower respira-
tory tract symptoms compared with older children, 
although this did not reach significance (22/149 (15%) 
children under 5 years versus 26/296 (8.7%), P=0.07). 
Parents sought medical review by the child’s primary 
care doctor in five cases, resulting in a change in man-
agement in three; one child was referred to hospital for 
further assessment but was discharged without admis-
sion after review.
Given the concern about wheeze after vaccination 
with LAIV, we analysed the change in asthma control 
test score for the four weeks after vaccination, from 
baseline. The score was determined at both time points 
for 394/445 (89%) participants with a history of asthma 
or recurrent wheeze. The asthma control test score did 
not significantly change for those aged 12 years and 
over (median change 0, P=0.12, fig 2). In those aged 2-11 
years, there was a small but significant improvement in 
the score after vaccination (median change 1, P<0.001). 
A similar improvement was also noted when the analy-
sis was restricted to children under 5 years (median 
change 1, P<0.001).
In the 29 participants who received a second dose of 
LAIV and who had complete follow-up, four experi-
enced an adverse event within 72 hours after immunisa-
tion. Two participants experienced a flare in eczema; in 
one this also occurred after the first dose of LAIV.
discussion
Systemic allergic reactions
In young people with egg allergy we did not observe any 
systemic allergic reactions or anaphylaxis after immu-
nisation with quadrivalent LAIV. Anaphylaxis is defined 
as a “severe, life-threatening generalized or systemic 
hypersensitivity reaction.”24 25 Thirty five percent of 
study participants had a history of anaphylaxis to egg: 
20% had experienced respiratory and/or cardiovascu-
lar involvement. In this study, participants with previ-
ous anaphylaxis to egg were not found to be at a higher 
risk of AEFI (of allergic cause, or otherwise) with LAIV.
Together with previous studies,26 27  the literature now 
reports 955 young people with egg allergy  (including 
338 (35%) with previous anaphylaxis to egg) who have 
received at least one dose of LAIV without an acute sys-
temic reaction. This gives an upper 95% confidence 
interval for the incidence of acute systemic allergic 
reaction in young people with egg allergy in the general 
table 1 | delayed adverse events 2-72 hours after immunisation with laiV as reported by 
parents
adverse events
no of children  
(n=762)
% rate (95% Ci)  
in cohort
Upper respiratory tract:
 Any symptoms 141 18.5 (15.8 to 21.4)
 Isolated symptoms only, <24 hours duration 72 9.4 (7.5 to 11.8)
 Isolated symptoms only, >24 hours duration 69 9.1 (7.1 to 11.3)
 Nasal symptoms with ocular involvement 1 0.1 (0.0 to 0.7)
Lower respiratory tract:
 Any symptoms 62 8.1 (6.3 to 10.3)
 Parent reported wheeze 29 3.8 (2.6 to 5.4)
Constitutional symptoms:
 Any 53 7.0 (5.2 to 9.0)
 Fever <24 hours 30 3.9 (2.7 to 5.6)
 Fever >24 hours 9 1.2 (0.5 to 2.2)
 Other: lethargy, headache, dizziness, myalgia 19 2.5 (1.5 to 3.9)
Dermatological:
 Flare in eczema 22 2.9 (1.8 to 4.3)
 Non-specific rash, no response to antihistamine 8 1.0 (0.5 to 2.1)
Abdominal symptoms:
 Vomiting, nausea, abdominal pain 2 0.3 (0.0 to 0.9)
 Loose stools 1 0.1 (0.0 to 0.7)
Ear, nose, and throat: mild nose bleed 6 0.8 (0.3 to 1.7)
Ocular: itch, redness 1 0.1 (0.0 to 0.7)
Neurological: any 0 0.0 (0.0 to 0.5)
Cardiovascular: any 0 0.0 (0.0 to 0.5)
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population of 0.39%, or less than 1 in 256 vaccinated 
young people with egg allergy. In young people with 
previous anaphylaxis to egg, the upper 95% confidence 
interval for the incidence of acute systemic reaction is 
1.09%. The incidence of possible local, IgE mediated 
reactions is higher (1.2%) than that previously reported 
for people without egg allergy.15  However, these reac-
tions were all mild, localised, and self limiting. Anaphy-
laxis to LAIV has been reported in adults (at a rate of 0.3 
reactions per 100 000 doses), but none were related to 
egg allergy.28  We have previously reported that LAIV is 
unlikely to contain enough egg protein to trigger an IgE 
mediated allergic reaction in people with egg allergy.29 
The risk of causing a systemic allergic reaction with 
quadrivalent LAIV therefore seems to be no greater in 
young people with egg allergy (including those with a 
history of anaphylaxis to egg) compared with those 
without egg allergy.
Following discussions with our local patient and 
public involvement panel, we chose to use an open 
design for this phase IV study, to maximise recruit-
ment to the study. Input from the panel indicated that 
it would not be as acceptable to include a placebo arm, 
nor would many parents consent for their offspring to 
be immunised with inactivated influenza vaccine 
when a non-injectable alternative was available. Thus, 
we can only compare risk of adverse events with his-
torical data.
This study confirms our previous findings that LAIV 
is unlikely to trigger a systemic allergic reaction in 
young people with egg allergy, with several important 
additions. Our earlier study provided initial data relat-
ing to the safety of LAIV in 282 young people with egg 
allergy26 ; however, the trivalent vaccine used in that 
study did not have detectable egg protein, thus the 
safety profile may have been due to a lack of egg protein 
in the vaccine batches used. In this study, the majority 
of the LAIV batches contained detectable ovalbumin. 
This, combined with the larger cohort size and a more 
representative population of young people with egg 
allergy, achieved by recruiting from non-tertiary allergy 
clinics, provides a stronger evidence base to support the 
safety of using LAIV in young people with egg allergy. 
In theory it is possible that previous vaccination with 
LAIV might result in sensitisation and an increased risk 
of subsequent reaction in future years. In this study, 
24% of the cohort received LAIV in 2013/14, and this was 
not associated with an increased risk of adverse events. 
Reassuringly, the rate of delayed adverse events in this 
study is similar to that previously reported after LAIV in 
non-atopic young people (table 2 ).4-7 9 15 28
wheeze after laiV
Guidelines from North America currently recommend 
against the use of LAIV in children under 5 years with a 
history of an episode of wheezing in the previous 12 
months,16  owing to concerns that the vaccine might 
cause wheezing in susceptible children, something not 
consistent with published data.4-6 15 30 31  An analysis of 
two randomised, multinational trials, in 1940 children 
aged 2 to 5 years with asthma or a history of wheezing, 
found no difference in the incidence of wheezing after 
vaccination between those who received LAIV and 
those who received trivalent influenza vaccine.32 How-
ever, both trials excluded children with wheeze in the 
42 days before receiving LAIV. Furthermore, previous 
studies have used “medically significant wheeze” in the 
42 days after vaccination as the outcome measure for 
lower respiratory tract symptoms. Although this may be 
a measure of more concerning wheeze, it is insensitive, 
as many parents of children with recurrent wheezing 
will manage their child’s symptoms at home without 
recourse to a medical professional. Parent reported 
wheeze is common in the autumn and winter months 
(when immunisation with LAIV is indicated). In this 
study, we only excluded children with acute wheezing 
in the previous three days, a more feasible scenario in 
terms of a targeted immunisation campaign. We did 
observe a higher rate of parent reported lower respira-
tory tract symptoms in children aged 2 to 5 years, but 
this did not reach statistical significance. To explore 
this further, we used the asthma control test question-
naire to assess asthma symptoms, including wheeze, in 
the four weeks before and after vaccination . We did not 
observe a significant increase in lower respiratory tract 
symptoms in children under 5 years of age receiving 
LAIV, nor was there a worsening in asthma control test 
scores. These data suggest that LAIV is safe in children 
with a history of asthma or recurrent wheeze in whom 
symptoms are well controlled.
Change in ACT score from baseline
Improved control
(fewer symptoms)
Worse control
(more symptoms)
Re
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e 
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)
-11
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-10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10
2-5 years 6-11 years ≥12 years
Fig 2 | Change in asthma control test (aCt) score at four weeks after immunisation with 
laiV compared with baseline in young people with a history of asthma or recurrent wheeze
table 2 | rates of adverse events within 72 hours after 
immunisation using laiV compared with rates in the 
literature
Symptoms within 72 hours
no (%)  
in study  
(n=779)
rates in  
literature 
(%)
Allergic reaction (mild symptoms) only 9 (1.2) 0.02
Allergic reaction: anaphylaxis 0 (0) 0
Fever 39 (5.0) 5.4
Nasal symptoms 141 (18.1) 31
Wheeze (parent reported) 29 (3.7) NR
Wheeze requiring treatment by doctor 3 (0.4) 0.2
Lower respiratory tract symptoms 62 (8.0) NR
Eczema flare 22 (2.8) NR
NR=not reported.
Rates reported as proportion of total number of doses given, to be 
consistent with method of reporting used in existing literature.15
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Strengths and limitations of this study
Our study population was recruited from a large num-
ber of secondary and tertiary allergy centres in the UK, 
and may therefore represent a cohort of young people 
with more severe allergy requiring specialist input. We 
therefore expect our findings to be applicable to a wider 
population of young people with egg allergy, including 
those with more mild allergy managed in primary care. 
We excluded those who had previously required venti-
lation on intensive care after an anaphylaxis triggered 
by egg. This, however, is an atypical occurrence, and we 
excluded no child because of this criterion. Anaphy-
laxis to food is not uncommon, with an estimated inci-
dence in children with food related allergy of 0.20 (95% 
confidence interval 0.09 to 0.43) cases per 100 person 
years.33  In contrast, fatal anaphylaxis is a rare event 
(although unpredictable), with an estimated incidence 
of 1.81 (95% confidence interval 0.94 to 3.45) cases per 
million person years.34  There are approximately 10 
fatalities due to food anaphylaxis in the UK per 
annum,35  compared with an annual average of 30-40 
admissions to intensive care due to food anaphylaxis 
(data obtained from UK Health and Social Care Informa-
tion Centre).36  The published data indicate that chil-
dren with egg allergy with a history of anaphylaxis are 
not more sensitive to lower doses of egg than those with 
only previous mild reactions.37 Taken together, these 
data suggest that LAIV is likely to be well tolerated even 
in those few children with previous anaphylaxis to egg 
requiring intensive care, although arguably it is reason-
able to expect such children to be vaccinated within an 
appropriate healthcare facility.
Conclusions and policy implications
This study provides evidence to support the revised 
Department of Health guidance for the 2015/16 season 
that, with the exception of children “with severe ana-
phylaxis to egg which has previously required intensive 
care, children with an egg allergy can be safely vacci-
nated with Fluenz Tetra® in any setting (including pri-
mary care and schools).”12 As with all settings providing 
vaccination, facilities should be available and staff 
trained to recognise and treat anaphylaxis. Further-
more, the vaccine is appropriate for use in children at 
risk of wheeze, in whom symptoms are well controlled 
and with no evidence of active wheezing in the 72 hours 
before immunisation.
We thank our data monitoring committee (Glenis Scadding (chair), 
Andrew Riordan, Giuseppina Rotiroti, and Andre Charlett) and our trial 
steering committee (Nicola Brathwaite (chair), Diab Haddad, and 
Hazel Gowland). We also thank our co-investigators in the SNIFFLE-2 
Study team and the UK Paediatric Vaccine Group for their support, as 
well as Public Health England colleagues for their support in data 
management: Samuel Lattimore, Deborah Cohen, Rashmi Malkani, 
and Teresa Gibbs. Finally, we thank the many parents and young 
people who participated in the study.
This report follows the TREND guidelines for the reporting quality of 
non-randomised evaluations of a public health intervention. Des 
Jarlais DC, Lyles C, Crepaz N, and the TREND Group (2004). Improving 
the reporting quality of nonrandomized evaluations of behavioral and 
public health interventions: the TREND statement. Am J Public Health 
2004;94:361-6.
The SNIFFLE-2 Study Investigators are: Richard Briggs (Warrington & 
Halton Hospitals NHS Foundation Trust), John Chapman (James Paget 
University Hospitals NHS Foundation Trust), Rahul Chodhari (Royal 
Free Hospital NHS Foundation Trust), Jonathan Cohen (University 
College London Hospitals NHS Foundation Trust), Iain Darwood (Wye 
Valley NHS Trust), Brenda DeWitt (Leeds Teaching Hospitals NHS Trust: 
Leeds Children’s Hospital), Christine Doyle (Alder Hey Children’s NHS 
Foundation Trust), Michel Erlewyn-Lajeunesse (University Hospital 
Southampton NHS Foundation Trust), Roisin Fitzsimons (NIHR 
Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation 
Trust), Keith Foote (Hampshire Hospital NHS Foundation Trust), James 
Gardner (Royal Free Hospital NHS Foundation Trust), Paul T Heath 
(Institute of Infection and Immunity, St George’s University of London), 
Donald Hodge (Leeds Teaching Hospitals NHS Trust: Leeds Children’s 
Hospital), Stephen M Hughes (Central Manchester University Hospitals 
NHS Foundation Trust), Nicola Jay (Sheffield Children’s Hospital NHS 
Foundation Trust), Susan Leech (King’s College Hospital NHS 
Foundation Trust), Colin Lumsden (Lancashire Teaching Hospitals NHS 
Foundation Trust), Nick Makwana (Sandwell and West Birmingham 
Hospitals NHS Trust), Louise J Michaelis (Great North Children’s 
Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust), 
Eleanor Minshall (Cambridge University Hospitals NHS Foundation 
Trust), Anita Modi (Luton and Dunstable University Hospital NHS 
Foundation Trust), Lee Noimark (Barts Health NHS Trust), Bernadette 
O’Connor (Ulster Hospital, South Eastern Health and Social Care Trust), 
KP Ramesh (Cambridgeshire Community Services NHS Trust), Martyn 
Rees (Shrewsbury and Telford Hospital NHS Trust), Jürgen Schwarze 
(University of Edinburgh and NHS Lothian), Matthew D Snape (NIHR 
Oxford Biomedical Research Centre and Oxford University Hospitals 
NHS Trust), Gary Stiefel (University Hospitals of Leicester NHS Trust), 
Huw M Thomas (University Hospitals Bristol NHS Foundation Trust), 
Paul J Turner (NIHR/Imperial Biomedical Research Centre and Asthma 
UK Centre in Allergic Mechanisms of Asthma, Imperial College 
London), Lynette Williams (Shrewsbury and Telford Hospital NHS 
Trust), and Natasha Zurick (Royal United Hospital Bath NHS Trust).
Contributors: PJT, MEL, JS, and EM conceived the study. PJT and MEL 
designed and managed the trial. NJA contributed to the statistical 
design, and together with PJT undertook data analysis. PJT and MEL 
drafted the report. All authors contributed to and reviewed the final 
report. PJT is guarantor for this work.
Funding: This report is independent research commissioned and 
funded by the Department of Health policy research programme 
(National Vaccine Evaluation Consortium, 039/0031). The views 
expressed in this publication are those of the author(s) and not 
necessarily those of the Department of Health. PJT is in receipt of a 
clinician scientist award (MR/K010468/1) funded by the Medical 
Research Council and has received research support from the 
Department of Health through the National Institute for Health 
Research (NIHR) comprehensive Biomedical Research Centre award to 
Imperial College London Healthcare NHS Trust. The study received 
additional local support through the NIHR Clinical Research Networks, 
with additional funding for the Edinburgh site from Health Protection 
Scotland and the Belfast site from Health & Social Care Services in 
Northern Ireland. The study design and data collection were 
performed independently of the funder; data analysis was performed 
in conjunction with Public Health England, who also contributed to the 
writing of this report. The study chief investigators (PJT and MEL) had 
full access to all the data in the study, and final responsibility for the 
decision to submit for publication. The sponsor of the study had no 
role in study design, data collection, data analysis, data interpretation, 
or writing of the report. 
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: PJT 
and MEL had financial support from the Department of Health for the 
submitted work; PJT has received research grants from the Medical 
Research Council and NIHR. All authors declare no financial 
relationships with any organisations that might have an interest in the 
submitted work in the previous three years; no other relationships or 
activities that could appear to have influenced the submitted work.
Ethical approval: This study was approved by the West Midlands-
Edgbaston research ethics committee (14/WM/0159) and the parent/
guardian of each participant gave written informed consent.
Data sharing: no additional data available.
Transparency: The manuscript’s guarantor (PJT) affirms that this 
manuscript is an honest, accurate, and transparent account of the 
study being reported; that no important aspects of the study have 
been omitted; and that any discrepancies from the study as planned 
(and, if relevant, registered) have been explained.
This is an Open Access article distributed in accordance with the terms 
of the Creative Commons Attribution (CC BY 4.0) license, which 
RESEARCH
See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
permits others to distribute, remix, adapt and build upon this work, for 
commercial use, provided the original work is properly cited. See: 
http://creativecommons.org/licenses/by/4.0/.
1 Baguelin M, Flasche S, Camacho A, et al. Assessing optimal target 
populations for influenza vaccination programmes: an evidence 
synthesis and modeling study. PLoS Med 2013;10:e1001527. 
2 JCVI statement on the routine annual influenza vaccination 
programme. 2015. www.gov.uk/government/publications/
jcvi-statement-on-the-routine-annual-influenza-vaccination-
programme.
3 Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness 
of influenza vaccines: a systematic review and meta-analysis. Lancet 
Infect Dis 2012;12:36-44.
4 Ambrose CS, Wu X, Knuf M, et al. The efficacy of intranasal live 
attenuated influenza vaccine in children 2 through 17 years of age: a 
meta-analysis of 8 randomized controlled studies. Vaccine 
2012;30:886-92. 
5 Tennis P, Toback SL, Andrews E, et al. A postmarketing evaluation of 
the frequency of use and safety of live attenuated influenza vaccine 
use in non-recommended children younger than 5 years. Vaccine 
2011;29:4947-52.
6 Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the 
safety of Ann Arbor strain live attenuated influenza vaccine in children 
aged 2-17 years. Influenza Other Respir Viruses 2011;5:389-97.
7 Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the 
safety of Ann Arbor strain live attenuated influenza vaccine in children 
5 through 17 years of age. Vaccine 2012;30:2989-98.
8 Kelso JM. Safety of influenza vaccines. Curr Opin Allergy Clin Immunol. 
2012;12:383-8.
9 Tennis P, Toback SL, Andrews EB, et al. A US postmarketing evaluation 
of the frequency and safety of live attenuated influenza vaccine use in 
nonrecommended children younger than 5 years: 2009-2010 season. 
Vaccine 2012;30:6099-102.
10 European Medicines Agency: Summary of Product Characteristics for 
Fluenz Tetra. 2015. www.ema.europa.eu/docs/en_GB/document_
library/EPAR_-_Product_Information/human/002617/
WC500158412.pdf.
11 Des Roches A, Paradis L, Gagnon R, et al. Egg-allergic patients can be 
safely vaccinated against influenza. J Allergy Clin Immunol 
2012;130:1213-6.e1.
12 Public Health England. Chapter 19: Influenza. In: Immunisation 
against infectious disease. Department of Health. 2014. www.gov.uk/
government/uploads/system/uploads/attachment_data/
file/347458/Green_Book_Chapter_19_v6_0.pdf.
13 NHS England. The national flu immunisation programme 2015/16. 
www.gov.uk/government/uploads/system/uploads/attachment_
data/file/418428/Annual_flu_letter_24_03_15__FINALv3_para9.pdf.
14 Nwaru BI, Hickstein L, Panesar SS, et al; EAACI Food Allergy and 
Anaphylaxis Guidelines Group. Prevalence of common food allergies 
in Europe: a systematic review and meta-analysis. Allergy 
2014;69:992-1007.
15 Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus 
inactivated influenza vaccine in infants and young children. N Engl J 
Med 2007;356:685-96.
16 Grohskopf LA, Sokolow LZ, Olsen SJ, et al. Prevention and control of 
influenza with vaccines: recommendations of the Advisory Committee 
on Immunization Practices, United States, 2015-16 influenza season. 
Morb Mortality Weekly Report (MMWR) 2015;64;818-825.
17 World Allergy Organization guidelines for the assessment and 
management of anaphylaxis. WAO J 2011;4:13-37.
18 British Thoracic Society and Scottish Intercollegiate Guidelines 
Network. British guideline on the management of asthma: a national 
clinical guideline. www.brit-thoracic.org.uk/document-library/
clinical-information/asthma/btssign-asthma-guideline-2014/.
19 Jia CE, Zhang HP, Lv Y, et al. The Asthma Control Test and Asthma 
Control Questionnaire for assessing asthma control: systematic 
review and meta-analysis. J Allergy Clin Immunol 2013;131: 
695-703.
20 Bousquet PJ, Combescure C, Klossek JM, et al. Change in visual analog 
scale score in a pragmatic randomized cluster trial of allergic rhinitis. 
J Allergy Clin Immunol 2009;123:1349-54.
21 Ruggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition 
and guidelines for data collection, analysis, and presentation of 
immunization safety data. Vaccine 2007;25:5675-84.
22 Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick 
testing in children with food allergy. Pediatr Allergy Immunol 
2004;15:435-41.
23 Sampson HA. Utility of food-specific IgE concentrations in predicting 
symptomatic food allergy. J Allergy Clin Immunol 2001;107:891-6.
24 Johansson SGO, Bieber T, Dahl R, et al. A revised nomenclature for 
allergy for global use: Report of the Nomenclature Review Committee 
of World Allergy Organization. J Allergy Clin Immunol 2004;113:832-6.
25 Muraro A, Roberts G, Worm M, et al., on behalf of EAACI Food Allergy 
and Anaphylaxis Guidelines Group. Anaphylaxis: Guidelines from the 
European Academy of Allergy and Clinical Immunology. Allergy 
2014;69:1026-45.
26 Turner PJ, Southern J, Andrews NJ, et al.; SNIFFLE Study Investigators. 
Safety of live attenuated influenza vaccine in atopic children with egg 
allergy. J Allergy Clin Immunol 2015;136:376-81.
27 Des Roches A, Samaan K, Graham F, et al. Safe vaccination of egg 
allergic patients with live attenuated influenza vaccine. J Allergy Clin 
Immunol Pract 2014;3:138-9.
28 Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following 
live, cold-adapted, intranasal influenza vaccine. JAMA 
2005;294:2720-5.
29 Turner PJ, Erlewyn-Lajeunesse M. Egg protein in the intranasal 
live-attenuated influenza vaccine (LAIV) is unlikely to cause 
egg-mediated allergic reactions in egg-allergic children. J Allergy Clin 
Immunol Pract 2015;3:312-3.
30 Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated 
influenza vaccine in children 2-7 years of age. Vaccine 2008;26(suppl 
4):D10-6.
31 Gaglani MJ, Piedra PA, Riggs M, et al. Safety of the intranasal, trivalent, 
live attenuated influenza vaccine (LAIV) in children with intermittent 
wheezing in an open-label field trial. Pediatr Infect Dis J 
2008;27:444-52.
32 Ambrose CS, Dubovsky F, Yi T, et al. The safety and efficacy of live 
attenuated influenza vaccine in young children with asthma or prior 
wheezing. Eur J Clin Microbiol Infect Dis. 2012;31:2549-57.
33 Umasunthar T, Leonardi-Bee J, Turner PJ, et al. Incidence of food 
anaphylaxis in people with food allergy: a systematic review and 
meta-analysis. Clin Exp Allergy 2015;45:1621-36.
34 Umasunthar T, Leonardi-Bee J, Hodes M, et al. Incidence of fatal food 
anaphylaxis in people with food allergy: a systematic review and 
meta-analysis. Clin Exp Allergy 2013;43:1333-41.
35 Turner PJ, Gowland MH, Sharma V, et al. Increase in hospital 
admissions due to anaphylaxis but no increase in fatalities: an 
analysis of UK national anaphylaxis data, 1992–2012. J Allergy Clin 
Immunol 2015;135:956-63.e1.
36 Vyas D, Ierodiakonou D, Harrison DA, et al. Increase in Intensive Care 
Unit Admissions for Anaphylaxis in the United Kingdom 2008-2012 
[Abstract]. Abstract presented at 2016 Annual Meeting of the 
American Academy of Allergy, Asthma & Immunology.
37 Eller, E. Hansen TK, Bindslev-Jensen C. Clinical thresholds to egg, 
hazelnut, milk and peanut: results from a single-center study using 
standardized challenges. Ann Allergy Asthma Immunol. 
2012;108:332-6.
© BMJ Publishing Group Ltd 2015
Supplementary information: table E1: adverse events 
following immunisation (AEFI) reported within two 
hours of live attenuated influenza vaccine (LAIV) being 
administered. Tables E2-E3: incidence of AEFI and 
delayed events following LAIV, by factor of interest
